← Natera, Inc. (NTRA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Natera, Inc. (NTRA)
Services-Medical Laboratories · market cap $56.5B · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
4
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Natera, Inc. (NTRA) is an Austin-based clinical genetic testing company specializing in cell-free DNA (cfDNA) technology across women's health, cancer screening, and organ health diagnostics. The company operates CAP-accredited, CLIA-certified laboratories and has grown revenue from $625M in 2021 to $2.306B in 2025, though it remains unprofitable. The next scheduled catalyst is Q2 2026 earnings on August 6, 2026.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Elacestrant | Phase 3 | ER-positive Breast Cancer |
| mFOLFOX6 3-6 month | Phase 3 | Stage III Colon Cancer |
| Discontinuation of the anti-HER2 maintenance therapy | Phase 2 | Metastatic Breast Cancer |
| Folfirinox | Phase 3 | Colorectal Cancer |
Price & technical context
3-month
+43.6%
6-month
+95.9%
12-month
+152.1%
52-wk range
$160.21–$414.52
vs 50-day MA
+23.1%
vs 200-day MA
+63.6%
Realized vol
47.3%
Max drawdown
-28.2%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for NTRA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.